Dengue is an arboviral disease of great clinical relevance among neglected diseases. It is transmitted by Dengue virus (DENV), which infects about 25 million people worldwide each year. So far there is no available licensed vaccine or specific drug to be used against DENV, but only palliative treatments to overcome the symptoms of the disease, considered a serious public health problem. Among the molecular targets verified as strategies for developing antivirals against DENV, we highlight the serine proteasic complex NS2B-NS3pro, essential for the viral maturation and replication. This molecular target is found conserved in all four serotypes, acting in major viral processes. In this context, this study aimed to understand various aspects related to DENV and especially the proteasic complex NS2B-NS3pro as a catalytic mechanism and candidate inhibitors of this pharmacological target applied to dengue.

No abstract